GPVI and GPIBα mediate Staphylococcal superantigen-like protein 5 (SSL5) induced platelet activation and direct toward glycans as potential inhibitors

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Hu, Houyuan ^a,b   Armstrong, Paul C J ^a   Khalil, Elie ^a   Chen, Yung Chih ^a,c   Straub, Andreas ^a   Li, Min ^a,b   Soosairajah, Juliana ^a   Hagemeyer, Christoph E ^a   Bassler, Nicole ^a   Huang, Dexing ^a   Ahrens, Ingo ^a   Krippner, Guy ^a   Gardiner, Elizabeth ^c   Peter, Karlheinz ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN VI; IMMUNOGLOBULIN G; PADGEM PROTEIN; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; SIALIDASE; STAPHYLOCOCCAL SUPERANTIGEN LIKE PROTEIN 5; STAPHYLOCOCCUS TOXIN; TYROSINE; UNCLASSIFIED DRUG; VIRULENCE FACTOR; ADHESION RECEPTOR; MEMBRANE PROTEIN; PLATELET MEMBRANE GLYCOPROTEIN VI; POLYSACCHARIDE; SULFATE; SUPERANTIGEN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; CARBOHYDRATE ANALYSIS; CELL STRAIN HL 60; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; ENZYME SPECIFICITY; METABOLISM; MOLECULAR GENETICS; STAPHYLOCOCCUS AUREUS; THROMBOCYTE;

STAPHYLOCOCCUS AUREUS;

BLOOD PLATELETS; CARBOHYDRATE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; HL-60 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; PLATELET ACTIVATION; PLATELET MEMBRANE GLYCOPROTEINS; POLYSACCHARIDES; STAPHYLOCOCCUS AUREUS; SUBSTRATE SPECIFICITY; SULFATES; SUPERANTIGENS; TYROSINE;

EID: 79955728776     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019190     Document Type: Article

References (37)

1. Petti CA, Fowler VG Jr, (2003) Staphylococcus aureus bacteremia and endocarditis. Cardiol Clin 21: 219-233, vii.
2. Moreillon P, Que YA, (2004) Infective endocarditis. Lancet 363: 139-149.
3. Kessler CM, Tang Z, Jacobs HM, Szymanski LM, (1997) The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 89: 4393-4401.
4. Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, et al. (2008) Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 52: 1430-1437.
5. Kerrigan SW, Cox D, (2009) Platelet-bacterial interactions. Cell Mol Life Sci 67: 513-523.
6. Fitzgerald JR, Foster TJ, Cox D, (2006) The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 4: 445-457.
7. Williams RJ, Ward JM, Henderson B, Poole S, O'Hara BP, et al. (2000) Identification of a novel gene cluster encoding staphylococcal exotoxin-like proteins: characterization of the prototypic gene and its protein product, SET1. Infect Immun 68: 4407-4415.
8. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, et al. (2002) Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359: 1819-1827.
9. Fitzgerald JR, Reid SD, Ruotsalainen E, Tripp TJ, Liu M, et al. (2003) Genome diversification in Staphylococcus aureus: Molecular evolution of a highly variable chromosomal region encoding the Staphylococcal exotoxin-like family of proteins. Infect Immun 71: 2827-2838.
10. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, et al. (2001) Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357: 1225-1240.
11. Al-Shangiti AM, Naylor CE, Nair SP, Briggs DC, Henderson B, et al. (2004) Structural relationships and cellular tropism of staphylococcal superantigen-like proteins. Infect Immun 72: 4261-4270.
12. Ramsland PA, Willoughby N, Trist HM, Farrugia W, Hogarth PM, et al. (2007) Structural basis for evasion of IgA immunity by Staphylococcus aureus revealed in the complex of SSL7 with Fc of human IgA1. Proc Natl Acad Sci U S A 104: 15051-15056.
13. Bestebroer J, Poppelier MJ, Ulfman LH, Lenting PJ, Denis CV, et al. (2007) Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood 109: 2936-2943.
14. Chung MC, Wines BD, Baker H, Langley RJ, Baker EN, et al. (2007) The crystal structure of staphylococcal superantigen-like protein 11 in complex with sialyl Lewis X reveals the mechanism for cell binding and immune inhibition. Mol Microbiol 66: 1342-1355.
15. Bestebroer J, van Kessel KP, Azouagh H, Walenkamp AM, Boer IG, et al. (2009) Staphylococcal SSL5 inhibits leukocyte activation by chemokines and anaphylatoxins. Blood 113: 328-337.
16. de Haas CJ, Weeterings C, Vughs MM, de Groot PG, Van Strijp JA, et al. (2009) Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibalpha and alpha IIb beta 3. J Thromb Haemost 7: 1867-1874.
17. Varki A, (2007) Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 446: 1023-1029.
18. Lopez JA, Ludwig EH, McCarthy BJ, (1992) Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region. Structure/function implications. J Biol Chem 267: 10055-10061.
19. Afshar-Kharghan V, Diz-Kucukkaya R, Ludwig EH, Marian AJ, Lopez JA, (2001) Human polymorphism of P-selectin glycoprotein ligand 1 attributable to variable numbers of tandem decameric repeats in the mucinlike region. Blood 97: 3306-3307.
20. Romo GM, Dong JF, Schade AJ, Gardiner EE, Kansas GS, et al. (1999) The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 190: 803-814.
21. Nieswandt B, Watson SP, (2003) Platelet-collagen interaction: is GPVI the central receptor? Blood 102: 449-461.
22. Baker HM, Basu I, Chung MC, Caradoc-Davies T, Fraser JD, et al. (2007) Crystal structures of the staphylococcal toxin SSL5 in complex with sialyl Lewis X reveal a conserved binding site that shares common features with viral and bacterial sialic acid binding proteins. J Mol Biol 374: 1298-1308.
23. Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, et al. (2003) The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 306: 1174-1181.
24. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, et al. (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271: 695-701.
25. Takamatsu D, Bensing BA, Cheng H, Jarvis GA, Siboo IR, et al. (2005) Binding of the Streptococcus gordonii surface glycoproteins GspB and Hsa to specific carbohydrate structures on platelet membrane glycoprotein Ibalpha. Mol Microbiol 58: 380-392.
26. Li S, Wang H, Peng B, Zhang M, Zhang D, et al. (2009) Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance. Proc Natl Acad Sci U S A 106: 4349-4354.
27. Arthur JF, Gardiner EE, Matzaris M, Taylor SG, Wijeyewickrema L, et al. (2005) Glycoprotein VI is associated with GPIb-IX-V on the membrane of resting and activated platelets. Thromb Haemost 93: 716-723.
28. Kato K, Kanaji T, Russell S, Kunicki TJ, Furihata K, et al. (2003) The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 102: 1701-1707.
29. Ruggeri ZM, Mendolicchio GL, (2007) Adhesion mechanisms in platelet function. Circ Res 100: 1673-1685.
30. Andrews RK, Gardiner EE, Shen Y, Whisstock JC, Berndt MC, (2003) Glycoprotein Ib-IX-V. Int J Biochem Cell Biol 35: 1170-1174.
31. Ali M, Hicks AE, Hellewell PG, Thoma G, Norman KE, (2004) Polymers bearing sLex-mimetics are superior inhibitors of E-selectin-dependent leukocyte rolling in vivo. FASEB J 18: 152-154.
32. Cheng X, Khan N, Mootoo DR, (2000) Synthesis of the C-glycoside analogue of a novel sialyl Lewis X mimetic. J Org Chem 65: 2544-2547.
33. Hallahan DE, Kuchibhotla J, Wyble C, (1997) Sialyl Lewis X mimetics attenuate E-selectin-mediated adhesion of leukocytes to irradiated human endothelial cells. Radiat Res 147: 41-47.
34. Kaila N, Thomas BE, (2002) Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin inhibitors. Med Res Rev 22: 566-601.
35. Beeh KM, Beier J, Meyer M, Buhl R, Zahlten R, et al. (2006) Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: A randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulmonary Pharmacology & Therapeutics 19: 233-241.
36. Meyer M, Beeh KM, Beier J, Beyer D, Aydt E, et al. (2007) Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males. British Journal of Clinical Pharmacology 63: 451-458.
37. Hicks AER, Abbitt KB, Dodd P, Ridger VC, Hellewell PG, et al. (2005) The anti-inflammatory effects of a selectin ligand mimetic, TBC-1269, are not a result of competitive inhibition of leukocyte rolling in vivo. J Leukoc Biol 77: 59-66.